Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

Ichnos’ Early-Stage Myeloma Asset Designed To Avoid ‘Pitfalls’ Of Magrolimab

Glenmark’s innovation subsidiary, Ichnos, highlights encouraging early data for lead bispecific antibody assets and hopes to accelerate these via licensing and partnership deals.The US-based arm also points to the tough biopharma financing market where investors are no longer satisfied with just the “preclinical story”.

Research & Development Clinical Trials

How To Turn Around A Struggling Biotech

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.

Companies Innovation

Deal Watch: OrsoBio Reveals Its Metabolic Health Focus With Four Licensing Pacts

California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.

Deal Watch Business Strategies

Keeping Track: AZ’s Imjudo, J&J’s Tecvayli Enter Burgeoning Immuno-Oncology Market; Genmab Submits Epcoritamab

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register